CAMP4 THERAPEUTICS CORPORATION (CAMP)
- Previous Close
1.9500 - Open
1.9991 - Bid --
- Ask --
- Day's Range
1.8707 - 2.0000 - 52 Week Range
1.6100 - 12.3000 - Volume
31,948 - Avg. Volume
39,371 - Market Cap (intraday)
38.709M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-11.0400 - Earnings Date Mar 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.66
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
www.camp4tx.comRecent News: CAMP
View More
Performance Overview: CAMP
Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CAMP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CAMP
View MoreValuation Measures
Market Cap
38.71M
Enterprise Value
-16.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.81
Price/Book (mrq)
0.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.80%
Return on Equity (ttm)
-101.99%
Revenue (ttm)
652k
Net Income Avi to Common (ttm)
-51.79M
Diluted EPS (ttm)
-11.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
64.04M
Total Debt/Equity (mrq)
13.83%
Levered Free Cash Flow (ttm)
-26.54M
Research Analysis: CAMP
View MoreResearch Reports: CAMP
View MoreInitiating coverage on CAMP
CALAMP CORP has an Investment Rating of SELL; a target price of $47.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about CAMP?
CALAMP CORP has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetLowering target price to $4.00
CALAMP CORP has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about CAMP?
CALAMP CORP has an Investment Rating of SELL; a target price of $5.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target